Keywords: BioTime, Glycosan, Cell Targetting, Stem cells, Regenerative medicine

BioTime signs deal to purchase Glycosan BioSystems assets; and Cell Targeting

Article | 15 February 2011

Print This

US biotech BioTime (NYSE Amex: BTX), a company that develops and markets products in the field of stem cells and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in